Hypertriglyceridemia is an increase in plasma triglycerides carried mainly by VLDL, chylomicrons, and particles derived from their metabolism. It is not a single disease: it encompasses common abnormalities associated with insulin resistance and environmental factors, secondary conditions, and rare genetic syndromes with severely impaired lipolysis. The same concentration may arise from different combinations of particle production and clearance, with different consequences.
150 mg/dL in fasting samples and 175 mg/dL in nonfasting samples are commonly used as descriptive reference values. Many documents define elevations from 500 mg/dL as severe, whereas around 1,000 mg/dL or above, chylomicrons and the risk of pancreatitis become particularly important. Classifications are not identical across all scientific societies: the measured value must be reported explicitly rather than relying on an adjective for the entire interpretation.
Two issues guide management. An increase in apoB-containing remnant lipoproteins contributes to atherosclerotic risk, while marked chylomicronemia predisposes to pancreatitis and recurrence. The two risks may coexist, but priorities change with the phenotype. A patient with triglycerides of 250 mg/dL and coronary artery disease requires a different approach from a young person with persistently elevated values above 2,000 mg/dL and recurrent pancreatitis.
Chylomicrons are produced in the intestine after fat absorption and contain apoB48; VLDL particles are produced in the liver and contain apoB100. Lipoprotein lipase, located on the luminal surface of the capillary endothelium, hydrolyzes triglycerides, making fatty acids available to tissues. ApoC-II facilitates its activity, while GPIHBP1 participates in transporting and anchoring the enzyme. ApoA-V, LMF1, and other regulators contribute to the efficiency of the system. Lipolysis transforms the particles and facilitates their subsequent clearance.
ApoC-III impairs the removal of triglyceride-rich lipoproteins through effects on lipolysis and hepatic uptake of remnants. ANGPTL3, ANGPTL4, and ANGPTL8 also modulate metabolism according to nutritional status and substrate distribution. This network explains why hypertriglyceridemia can occur without a structural lipoprotein lipase defect and why some therapies targeting apoC-III may work even when lipolytic activity is profoundly impaired.
Common forms often reflect VLDL overproduction and relatively inefficient clearance. Insulin resistance increases fatty acid flux from adipose tissue to the liver; excess energy intake and sugars promote hepatic synthesis, while alcohol and uncontrolled diabetes can amplify the process. Once clearance capacity is exceeded, the increase can become nonlinear: an additional precipitating factor produces a much larger rise than would be seen under more favorable metabolic conditions.
Multifactorial chylomicronemia usually results from an interaction between polygenic predisposition, sometimes heterozygous variants in lipolysis-related genes, and secondary factors. It tends to present more often in adulthood and may fluctuate substantially with weight, blood glucose, alcohol, and medications. The presence of VLDL and remnants contributes to cardiovascular risk. It should not be considered benign merely because a classic recessive defect is not identified: some persistent forms carry a very high risk of pancreatitis.
Familial chylomicronemia syndrome (FCS), by contrast, is a rare, usually recessive condition due to biallelic variants in LPL or genes needed for its function, including APOC2, APOA5, GPIHBP1, and LMF1. Chylomicron clearance is impaired even without common precipitating factors. Early onset, persistently extreme levels, pancreatitis, and limited response to conventional therapies support suspicion. Atherosclerotic risk may be less pronounced than in the remnant-rich multifactorial phenotype, but it must not be declared absent in every patient.
Secondary causes include poorly controlled diabetes, visceral obesity, hypothyroidism, kidney disease, pregnancy, some liver diseases, and lipodystrophies. Glucocorticoids, retinoids, oral estrogens, certain antipsychotics, immunosuppressants, and antiretroviral agents may contribute. In very severe cases, more than one factor should be sought, because several moderate abnormalities may overwhelm an already reduced lipolytic capacity. Rare acquired forms are also possible, including autoimmune conditions that interfere with proteins of the lipolytic pathway.
Atherogenicity is mainly related to remnant particles, which contain cholesterol and can enter the arterial intima when their size permits. Measured triglyceride is therefore also a marker of particle metabolism, rather than simply a substance deposited as such in the arterial wall. ApoB particle number and cholesterol content help explain why two individuals with the same triglyceride level may have different vascular risk.
In pancreatitis, chylomicron accumulation, microcirculatory disturbances, and the release of potentially toxic quantities of fatty acids all contribute. The risk threshold is not identical for everyone: previous pancreatitis, persistent elevation, and triggers modify the likelihood. Pancreatic injury can in turn impair insulin secretion and worsen metabolic control, creating an unfavorable clinical cycle.
Mild or moderate elevations are usually asymptomatic and are detected during routine testing or risk assessment. The magnitude of elevation cannot be inferred from fatigue, headache, or nonspecific digestive symptoms. In extreme cases, eruptive xanthomas, lipemia retinalis, and hepatosplenomegaly may occur; plasma may appear milky. These findings are suggestive but do not replace measurement or establish the cause on their own.
Acute pancreatitis typically presents with severe abdominal pain, often epigastric and radiating to the back, nausea, and vomiting. It may progress to a systemic inflammatory response and organ failure. A patient with very high triglycerides and compatible pain requires urgent assessment. Lipase or amylase assays may be affected by interference from a lipemic sample: an unexpected result cannot exclude the diagnosis without clinical assessment and, when indicated, analytical or imaging investigations.
The chronological history should identify the first abnormal result, periods of normalization, the highest documented levels, and associated conditions. Extreme levels occurring only during diabetic decompensation point to a different explanation from chylomicronemia present since childhood. Episodes of unexplained abdominal pain, previous hospital admissions, and pancreatitis in relatives may be important even when a lipid profile was not obtained at the time. Usual diet, alcohol, medications, and recent weight changes should be recorded.
The physical examination assesses fat distribution, blood pressure, signs of insulin resistance, hepatomegaly, xanthomas, and findings related to secondary causes. The absence of obesity does not rule out severe disease; lipodystrophy may combine little subcutaneous fat with severe insulin resistance. In FCS, the burden of illness also includes dietary restrictions, fear of recurrence, and interference with social life and work, all of which affect adherence and warrant explicit assessment.
Characterizing a significant elevation requires fasting triglycerides and a complete lipid profile, with repeat measurements when possible. A nonfasting sample may reveal the problem, but standardized confirmation helps distinguish a postprandial response from pathological persistence. In pancreatitis, blood should be sampled early because fasting and treatment can rapidly lower triglycerides and obscure the value that contributed to the event.
With elevated triglycerides, calculated LDL-C may be unreliable; the Friedewald formula cannot be used from 400 mg/dL upward. Even a direct assay may have limitations in extreme lipemia. Non-HDL cholesterol and apoB complete the assessment, although they too require a reliable sample and method. Relatively low apoB compared with markedly elevated triglycerides is consistent with a small number of very large, triglyceride-rich particles, whereas numerous VLDL particles and remnants tend to produce a different profile.
Persistence is evaluated after secondary factors have been addressed and a reasonable period of intervention, without delaying care for weeks when pancreatitis risk is immediate. The 2025 NLA/ASPC consensus proposes defining persistent chylomicronemia as triglycerides of at least 1,000 mg/dL in more than half of the available measurements. This criterion describes a pattern, not a mutation, and should not be calculated using samples selected only during hospital admissions or particularly favorable periods.
Alarm features include recurrent pancreatitis, repeated episodes of severe unexplained abdominal pain, pancreatitis beginning in childhood, relevant family history, and markedly reduced lipolytic activity when documented. Their presence identifies the need for intensive prevention even when genetic testing does not demonstrate FCS. Modern classification therefore considers both etiology and clinical severity, so that a negative test does not exclude a patient with significant recurrences from specialist care.
A diagnosis of FCS is supported by the combined history, lipid profile, treatment response, and genetic findings. Clinical scoring systems can help select people for molecular testing but do not replace interpretation. Compatible biallelic variants in lipolytic pathway genes are sought; a single variant or a variant of uncertain significance does not automatically establish the recessive syndrome. Multifactorial forms may have a substantial genetic component without following simple Mendelian inheritance.
Etiological investigation includes blood glucose and HbA1c, thyroid function, kidney function, proteinuria, and liver assessment, as well as reviewing medication and alcohol use. Differential diagnoses include dysbetalipoproteinemia, familial combined dyslipidemia, and lipodystrophies, in which particle composition and associated manifestations differ. An isolated result cannot distinguish these conditions; the pattern after diabetes control or agreed withdrawal of a contributing medication can be very informative.
In severely lipemic samples, analytical interference must be considered, including pseudohyponatremia with indirect methods, and discussed with the laboratory. Even an apparently high but inconsistent triglyceride result may require exclusion of interference from free glycerol. The result should not be corrected empirically: verification uses appropriate methods and addresses a specific discrepancy between clinical findings and laboratory data.
Once the cause has been established, pancreatic and vascular priorities are distinguished. The frequency of extreme elevations, previous pancreatitis, and inability to maintain control guide the former; atherosclerotic disease, apoB, non-HDL cholesterol, and other factors guide the latter. A lower result after an acute episode does not settle the issue if the patient usually returns to extreme levels in everyday life.
When pancreatitis is suspected, diagnosis follows clinical, biochemical, and imaging criteria: two of the following are generally required—typical pain, pancreatic enzymes more than three times the upper limit, and compatible imaging findings. Pancreatitis severity depends primarily on organ failure and complications, not on the triglyceride peak alone. Ultrasonography and other investigations also look for concurrent causes, such as gallstones; attributing the event to lipids does not automatically exclude a second etiology.
In recurrent disease, pancreatic function, diabetes resulting from injury, and possible local complications are assessed. Nutritional counseling should assess energy intake, essential fatty acids, and fat-soluble vitamins when the diet is very low in fat. If informative, genetic testing guides family counseling and reproductive planning. Vascular investigations remain guided by symptoms and clinical usefulness, without indiscriminate instrumental screening for every triglyceride elevation.
In common forms, treatment first addresses energy balance, refined carbohydrates, alcohol, and glycemic control. Weight loss when indicated and physical activity improve VLDL metabolism. These measures can have substantial effects, but individual response depends on predisposition. Treating hypothyroidism and other causes helps stabilize the profile; potentially contributing medications are reassessed with the specialist who prescribed them.
In chylomicronemia, the amount of dietary fat has a more direct role, because chylomicrons originate from intestinal absorption. Severe forms may require a diet with fat providing around 10–15% of energy or approximately 20–30 g per day, individualized to the patient, and sometimes further temporary restrictions. In FCS, the plan is long-term and requires nutritional expertise. Medium-chain triglycerides can contribute to energy intake in selected cases but do not replace essential fatty acids and monitoring. Alcohol must be eliminated in severe forms.
When atherosclerotic risk predominates, statins remain central according to overall risk, even though triglycerides are not their only target. Good LDL-C does not justify ignoring persistently elevated non-HDL cholesterol or apoB. LDL reduction may require ezetimibe or additional therapies, while triglycerides are managed in parallel. It is not necessary to normalize every metabolic parameter before initiating clearly indicated cardiovascular prevention.
Fibrates modulate PPAR-alpha and can substantially lower triglycerides when some lipolytic capacity remains. Response varies and may be poor in FCS. Fenofibrate is generally preferred when combination with a statin is needed, whereas gemfibrozil has more problematic muscle-related interactions. Kidney function, possible changes in creatinine, transaminases, and biliary risk inform selection and monitoring. Using these agents to lower severely elevated levels does not amount to uniform proof of cardiovascular event prevention in all populations.
Prescription omega-3 preparations at appropriate doses can lower triglycerides; composition, purity, and indication matter. Icosapent ethyl, purified EPA, demonstrated cardiovascular benefit in REDUCE-IT in selected statin-treated patients with moderately elevated triglycerides. The therapeutic dose is 2 g twice daily in indicated settings, while considering atrial fibrillation and bleeding risks. This finding cannot be extrapolated to any EPA/DHA mixture or commercial supplement.
The distinction between biomarker and outcome is illustrated by PROMINENT: pemafibrate lowered triglycerides and certain remnant markers but did not reduce cardiovascular events in the population studied. Lowering triglycerides therefore does not, by itself, prove a reduction in myocardial infarctions. Similarly, evidence on preventing pancreatitis must be evaluated separately from atherosclerotic outcomes because the populations, mechanisms, and study durations differ.
Therapies targeting apoC-III have expanded treatment options in severe forms. Volanesorsen, an antisense oligonucleotide, lowers triglycerides but requires particular attention to thrombocytopenia and local reactions. Olezarsen uses an antisense strategy with hepatic targeting and, in the 2024 BALANCE trial, showed lipid reduction and fewer episodes of pancreatitis in FCS. In the CORE and CORE2 trials, published in 2026, evaluation was extended to populations with severe hypertriglyceridemia, showing reductions in triglycerides and pancreatic events in the comparisons specified by the studies.
Plozasiran reduces apoC-III synthesis through small interfering RNA. PALISADE studied patients with persistent chylomicronemia, with or without genetic confirmation, and demonstrated marked lipid reduction and a lower risk of pancreatitis during the observation period. This evidence does not make treatments interchangeable or automatically indicated for moderate elevation. Selection, monitoring for glycemic and other adverse effects, approvals, and access must be checked for the specific molecule and national setting.
In acute pancreatitis, management follows the principles of pancreatic disease care: severity assessment, individualized fluid therapy, analgesia, nutritional support, and management of complications. Initially stopping intake that fuels chylomicronemia and controlling precipitating factors can rapidly reduce triglycerides. Prolonged fasting is not an independent therapeutic goal: nutrition is resumed according to tolerance and clinical status, with an appropriate composition.
Intravenous insulin is appropriate when significant hyperglycemia or ketoacidosis must be treated, with monitoring of glucose and potassium. It is not mandatory for every case of hypertriglyceridemia-associated pancreatitis in the absence of diabetes. Heparin is not routinely used to release lipoprotein lipase, given the transient effect, possible subsequent enzyme depletion, and bleeding risk. Plasmapheresis can rapidly lower the value, but evidence that it improves outcomes compared with conventional therapy is limited; it is not a universal first-line treatment and may be discussed in selected situations, including obstetric cases.
During pregnancy, the physiological increase in triglycerides can precipitate chylomicronemia in predisposed women. When the diagnosis is known, planning before conception is useful, with progressively intensified surveillance and an obstetric, lipidology, and nutrition team. Medication choice is constrained by safety data and does not automatically follow the regimen used for nonpregnant adults. Extreme levels, pain, and a history of pancreatitis require more intensive care.
Follow-up measures both lipid response and the absence of recurrence. Monitoring is frequent during severe phases; after stabilization, its frequency is adapted to risk, changes in treatment, and the ability to maintain the diet. One initial practical goal is to move out of the range associated with high pancreatitis risk, often aiming for triglycerides below 500 mg/dL, followed by optimization of the overall profile. In refractory forms, diagnosis, actual dietary intake, diabetes, medications, and the availability of targeted therapies should be reassessed.
Prognosis depends more on etiology and persistence than on a single peak measurement. A multifactorial form may improve substantially after correction of precipitating factors but can recur with a new exposure. FCS generally requires lifelong management. In both cases, reducing the frequency and duration of chylomicronemia episodes is a concrete clinical goal, not merely a cosmetic improvement in a laboratory report.
Pancreatic complications include necrosis, fluid collections, infection, organ failure, and death in the most severe acute cases. Recurrences may compromise exocrine and endocrine function, leading to maldigestion and diabetes. The risk of another episode makes a post-discharge strategy necessary even when the patient feels well and triglycerides have temporarily improved.
Vascular risk is particularly relevant in phenotypes rich in VLDL and remnants, especially with diabetes, elevated apoB, and other risk factors. Myocardial infarction, atherosclerotic stroke, and peripheral arterial disease remain possible even after triglycerides leave the range associated with pancreatitis risk. Normalization of triglycerides therefore does not automatically complete cardiovascular prevention: residual lipoprotein burden and other exposures must also be assessed and managed.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.